Based on our findings, we propose that the bioactivity of WIB is mediated through AMPK activation, which modulates adipose tissue formation and liver metabolism, ultimately contributing to the inhibition of lipogenesis and anti-obesity effects [66,67]. This evidence concerns the gene PRKAA1 and obesity due to melanocortin 4 receptor deficiency.